نتائج البحث - Suresh Agarwal

  • يعرض 1 - 18 نتائج من 18
تنقيح النتائج
  1. 1
    Regulation of Chondrocytic Gene Expression by Biomechanical Signals

    Regulation of Chondrocytic Gene Expression by Biomechanical Signals حسب Thomas J. Knobloch, S. Madhavan, Jin Nam, Suresh Agarwal, Sudha Agarwal

    منشور في 2008
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Patterns of Facial Fractures and Protective Device Use in Motor Vehicle Collisions From 2007 to 2012

    Patterns of Facial Fractures and Protective Device Use in Motor Vehicle Collisions From 2007 to 2012 حسب David A. Hyman, Sandeep Saha, Harry S. Nayar, John F. Doyle, Suresh Agarwal, Scott R. Chaiet

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Which Complications Matter Most? Prioritizing Quality Improvement in Emergency General Surgery

    Which Complications Matter Most? Prioritizing Quality Improvement in Emergency General Surgery حسب John Scarborough, Jessica R. Schumacher, Theodore N. Pappas, C. Cameron McCoy, Brian R. Englum, Suresh Agarwal, Caprice C. Greenberg

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor, in patients with non‐Hodgkin lymphoma

    Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor, in patients with non‐Hodgkin lymphoma حسب Suresh Agarwal, Ahmed Hamed Salem, Alexey V. Danilov, Beibei Hu, Soham D. Puvvada, Martin Gutierrez, David Chien, Lionel D. Lewis, Shekman Wong

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

    Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refra... حسب Marion Subklewe, Anthony S. Stein, Roland B. Walter, Ravi Bhatia, Andrew H. Wei, David Ritchie, Veit Bücklein, Pankit Vachhani, Tian Dai, Antreas Hindoyan, Suresh Agarwal, Abraham Anderson, Sophia K. Khaldoyanidi, Farhad Ravandi

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Long‐term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post‐treatment

    Long‐term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post‐treatment حسب Emily Symington, Savita Rangarajan, Will Lester, Bella Madan, Glenn F. Pierce, Priyanka Raheja, Tara M. Robinson, Dane Osmond, Chris B. Russell, Christian Vettermann, Suresh Agarwal, Mingjin Li, Wing Yen Wong, Michael Laffan

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A

    Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A حسب Brian R Long, Tara M. Robinson, Jonathan R S Day, Hua Yu, Kelly Lau, Urooj Imtiaz, Kathryn Patton, Greg de Hart, Joshua Henshaw, Suresh Agarwal, Christian Vettermann, Stephen J. Zoog, Soumi Gupta

    منشور في 2024
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites

    Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites حسب Hong Liu, Melissa J. Michmerhuizen, Yanbin Lao, Katty Wan, Ahmed Hamed Salem, James W. Sawicki, Michael D. Serby, Vaidyanathan Srirajan, Shekman Wong, Suresh Agarwal, Martin Dunbar, Jens Sydor, Sonia M. de Morais, Anthony Lee

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

    Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy حسب Steven Coutré, Michael Y. Choi, Richard R. Furman, Herbert Eradat, Leonard T. Heffner, Jeffrey A. Jones, Brenda Chyla, Lang Zhou, Suresh Agarwal, Tina Waskiewicz, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, William G. Wierda, Matthew S. Davids

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Mechanosignaling in Bone Health, Trauma and Inflammation

    Mechanosignaling in Bone Health, Trauma and Inflammation حسب Derrick M. Knapik, P. Perera, Jin Nam, Alisa D. Blazek, Björn Rath, Binnaz Leblebicioğlu, Hiranmoy Das, Lai‐Chu Wu, Timothy E. Hewett, Suresh Agarwal, Alexander G. Robling, David C. Flanigan, Beth S. Lee, Sudha Agarwal

    منشور في 2013
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Surgical management of pancreatic necrosis

    Surgical management of pancreatic necrosis حسب Nathan T. Mowery, Brandon R. Bruns, Heather MacNew, Suresh Agarwal, Toby M. Enniss, Mansoor Khan, Weidun Alan Guo, Jeremy W. Cannon, Matthew Lissauer, Therèse M. Duane, Amy N. Hildreth, Peter A. Pappas, Lynn Gries, Meghann L. Kaiser, Bryce R. H. Robinson

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia

    Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia حسب Andrew H. Wei, Stephen A. Strickland, Gail J. Roboz, Jing‐Zhou Hou, Walter Fiedler, Tara L. Lin, Giovanni Martinelli, Roland B. Walter, Anoop K. Enjeti, Kaffa Fakouhi, David E. Darden, Martin Dunbar, Ming Zhu, Suresh Agarwal, Ahmed Hamed Salem, Mack Mabry, John Hayslip

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Successful Nonoperative Management of the Most Severe Blunt Liver Injuries

    Successful Nonoperative Management of the Most Severe Blunt Liver Injuries حسب Gwendolyn M. van der Wilden, George C. Velmahos, Timothy A. Emhoff, Samielle K. Brancato, Charles A. Adams, Georgios Georgakis, Lenworth M. Jacobs, Ronald L. Gross, Suresh Agarwal, Peter Burke, Adrian A. Maung, Dirk C. Johnson, Robert J. Winchell, Jonathan D. Gates, Walter Cholewczynski, Michael S. Rosenblatt, Yuchiao Chang

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

    Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma حسب Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto, Joseph Mıkhael, Ravi Vij, Brigitte Pegourié, Lofti Benboubker, Thierry Façon, Martine Amiot, Philippe Moreau, Elizabeth A. Punnoose, Stefanie Alzate, Martin Dunbar, Tu Xu, Suresh Agarwal, Sari H. Enschede, Joel D. Leverson, Jeremy A. Ross, Paulo Maciag, Maria Verdugo, Cyrille Touzeau

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

    Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study حسب Sven de Vos, L. J. Swinnen, Dee Dee Wang, Erin Reid, Nicole Fowler, Jaclyn Cordero, Martin Dunbar, Sari H. Enschede, Cathy E. Nolan, Adam M. Petrich, Jeremy A. Ross, Ahmed Hamed Salem, Maria Verdugo, Suresh Agarwal, Lang Zhou, Mark Kozloff, Loretta J. Nastoupil, Christopher R. Flowers

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

    Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study حسب Andrew H. Wei, Stephen A. Strickland, Jing-Zhou Hou, Walter Fiedler, Tara L. Lin, Roland B. Walter, Anoop K. Enjeti, Ing Soo Tiong, Michael R. Savona, Sang‐Min Lee, Brenda Chyla, Relja Popovic, Ahmed Hamed Salem, Suresh Agarwal, Tu Xu, Kaffa Fakouhi, Rod Humerickhouse, Wan-Jen Hong, John Hayslip, Gail J. Roboz

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

    Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study حسب John F. Seymour, Shuo Ma, Danielle M. Brander, Michael Y. Choi, Jacqueline C. Barrientos, Matthew S. Davids, Mary Ann Anderson, Anne Beaven, Steven T. Rosen, Constantine S. Tam, Betty Prine, Suresh Agarwal, Wijith Munasinghe, Ming Zhu, Leanne Lash, Monali Desai, Elisa Cerri, Maria Verdugo, Su Young Kim, Rod Humerickhouse, Gary Gordon, Thomas J. Kipps, Andrew W. Roberts

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Statins enhance efficacy of venetoclax in blood cancers

    Statins enhance efficacy of venetoclax in blood cancers حسب J. Scott Lee, Andrew W. Roberts, Dennis Juarez, Thanh-Trang T. Vo, Shruti Bhatt, Lee-or Herzog, Sharmila Mallya, Richard J. Bellin, Suresh Agarwal, Ahmed Hamed Salem, Tu Xu, Jia Jia, Lingxiao Li, John R. Hanna, Matthew S. Davids, Angela G. Fleischman, Susan O’Brien, Lloyd T. Lam, Joel D. Leverson, Anthony Letai, Jonathan H. Schatz, David A. Fruman

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: